Literature DB >> 23085453

The macroeconomics of dementia--will the world economy get Alzheimer's disease?

Sube Banerjee1.   

Abstract

BACKGROUND: Health is firmly on the economic radar. It is big business. In 2009, the proportion of the Gross Domestic Product spent on health care varied between 6.4% in Mexico and 17.4% in the U.S., with the UK at 9.8% and Germany, Switzerland and Canada ∼11%. These are considerable amounts of money and they are growing. With all projections pointing to a growth in the numbers of older people, the pressure on budgets will only increase. In this paper we will consider the role of dementia in this.
METHODS: Demographic and economic data were combined and policy implications developed.
RESULTS: The costs of dementia dwarf those of the illnesses that are currently prioritized at a national and international level such as HIV, cancer, heart disease, stroke and diabetes. Based on simple demographics, the costs of dementia are set to increase by 85% by 2030, with developing countries bearing an increasing share of the economic burden.
CONCLUSIONS: The data suggest that dementia is a clear and present economic challenge for the world from the macro level down to the individual. Before the crisis, governmental structural primary deficits were generally improving and this would have given time and resource to meet the challenges of ageing in general and dementia in particular. However, increasing government debt over the past 3 years has had the effect of our needing to implement reforms to contain the risks to sovereign budgets sooner rather than later. This is not an issue that can be ignored. Inaction will only lead to further debt accumulation in the medium term and the death of systems of care in the long term. Across the developed world, the main long-term fiscal challenges come from health care costs, and dementia is a major driver of those costs. There is a need for budgetary consolidation and pension reform more generally. But, given that dementia is the highest ticket health and social care item that we have, making up 60% of long term care spending according to some estimates, then targeted investment in early intervention and in research (into causes, cure and care) are likely to be of major value in personal, societal, political, and economic terms.
Copyright © 2012 IMSS. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23085453     DOI: 10.1016/j.arcmed.2012.10.006

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  13 in total

1.  Neural stem cells isolated from amyloid precursor protein-mutated mice for drug discovery.

Authors:  Vito Antonio Baldassarro; Giulia Lizzo; Michela Paradisi; Mercedes Fernández; Luciana Giardino; Laura Calzà
Journal:  World J Stem Cells       Date:  2013-10-26       Impact factor: 5.326

2.  Family-based genome scan for age at onset of late-onset Alzheimer's disease in whole exome sequencing data.

Authors:  M Saad; Z Brkanac; E M Wijsman
Journal:  Genes Brain Behav       Date:  2015-09-23       Impact factor: 3.449

3.  Incidence of mild cognitive impairment in the elderly population in Greece: results from the HELIAD study.

Authors:  George S Vlachos; Mary H Kosmidis; Mary Yannakoulia; Efthimios Dardiotis; Georgios Hadjigeorgiou; Ioanna Tzoulaki; Andrea N Georgiou; Paraskevi Sakka; Costas A Anastasiou; Leonidas Stefanis; Nikolaos Scarmeas
Journal:  Aging Clin Exp Res       Date:  2021-03-08       Impact factor: 3.636

4.  Characterising Australian memory clinics: current practice and service needs informing national service guidelines.

Authors:  Sharon L Naismith; Johannes C Michaelian; Lee-Fay Low; Valerie Arsenova; Inga Mehrani; Katrina Fyfe; Nicole A Kochan; Susan E Kurrle; Christopher Rowe; Perminder S Sachdev
Journal:  BMC Geriatr       Date:  2022-07-14       Impact factor: 4.070

5.  Genetic variation of oxidative phosphorylation genes in stroke and Alzheimer's disease.

Authors:  Alessandro Biffi; Mert R Sabuncu; Rahul S Desikan; Nick Schmansky; David H Salat; Jonathan Rosand; Christopher D Anderson
Journal:  Neurobiol Aging       Date:  2014-02-05       Impact factor: 4.673

6.  Microtubule stabilising peptides rescue tau phenotypes in-vivo.

Authors:  Shmma Quraishe; Megan Sealey; Louise Cranfield; Amritpal Mudher
Journal:  Sci Rep       Date:  2016-12-02       Impact factor: 4.379

7.  Virus Infections on Prion Diseased Mice Exacerbate Inflammatory Microglial Response.

Authors:  Nara Lins; Luiz Mourão; Nonata Trévia; Aline Passos; José Augusto Farias; Jarila Assunção; Amanda Quintairos; João Bento-Torres; Marcia Consentino Kronka Sosthenes; José Antonio Picanço Diniz; Pedro Fernando da Costa Vasconcelos; Cristovam Wanderley Picanço-Diniz
Journal:  Oxid Med Cell Longev       Date:  2016-11-27       Impact factor: 6.543

Review 8.  Predicting dementia from primary care records: A systematic review and meta-analysis.

Authors:  Elizabeth Ford; Nicholas Greenslade; Priya Paudyal; Stephen Bremner; Helen E Smith; Sube Banerjee; Shanu Sadhwani; Philip Rooney; Seb Oliver; Jackie Cassell
Journal:  PLoS One       Date:  2018-03-29       Impact factor: 3.240

9.  Improving Brain Magnetic Resonance Image (MRI) Segmentation via a Novel Algorithm based on Genetic and Regional Growth.

Authors:  Javadpour A; Mohammadi A
Journal:  J Biomed Phys Eng       Date:  2016-06-01

10.  Analysis of the Cerebrospinal Fluid Proteome in Alzheimer's Disease.

Authors:  Payam Emami Khoonsari; Anna Häggmark; Maria Lönnberg; Maria Mikus; Lena Kilander; Lars Lannfelt; Jonas Bergquist; Martin Ingelsson; Peter Nilsson; Kim Kultima; Ganna Shevchenko
Journal:  PLoS One       Date:  2016-03-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.